FEDERALhearing transcript

Congressional Hearing on Synthetic Drug Dangers

Original title: SYNTHETIC DRUGS, REAL DANGER

January 1, 2016

synthetic drugs drug enforcement public health criminal justice opioid epidemic

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing serves as a formal legislative record for evaluating federal policy and enforcement strategies regarding the regulation of synthetic substances in the United States.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Drug Enforcement Administration

The agency is responsible for implementing and enforcing federal regulations regarding controlled substances.

General Public

The public is affected by the availability and regulation of synthetic drugs in their communities.

What changed

Last recorded activity January 1, 2016.

What's next

Next step not available in the current record.

Summary

This document is the official record of a 2016 House Judiciary Subcommittee hearing regarding the risks and regulation of . The hearing featured testimony from law enforcement, the DEA, and medical experts to discuss the challenges of addressing these substances.

Key Facts

The hearing took place on May 17, 2016, in the Rayburn House Office Building.
The session was held by the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
The hearing focused on the public safety and health risks associated with synthetic drugs.
Testimony was provided by representatives from the DEA, the Fraternal Order of Police, the Connor Project Foundation, and academia.
The hearing record includes prepared statements from witnesses and members of Congress.

Why It Matters

The hearing serves as a formal legislative record for evaluating federal policy and enforcement strategies regarding the regulation of synthetic substances in the United States.

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was held to examine the dangers and regulatory challenges posed by in the United States.

Who testified at the hearing?

Witnesses included officials from the DEA, the Fraternal Order of Police, the Connor Project Foundation, and a professor from the University of North Carolina.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Legislative focus on synthetic drugs

The hearing highlights a 2016 legislative effort to address the rapid evolution of synthetic drug formulas.

Drug Enforcement Administration

Connected Entities

personLouis J. Milione“Deputy Assistant Administrator, DEA Office of Diversion Control”Map →

personDevin Eckhardt“Founder of the Connor Project Foundation”Map →

personKen Buck“Acting Chairman of the Subcommittee”Map →

personWilliam Smith, Jr.“Representative of the Fraternal Order of Police”Map →

personDavid Earl Nichols“Adjunct Professor at the University of North Carolina at Chapel Hill”Map →

organizationDrug Enforcement Administration“Federal agency responsible for drug enforcement”Map →

organizationHouse Subcommittee on Crime, Terrorism, Homeland Security, and Investigations“The committee conducting the hearing”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance60
How much this matters to a regular citizen
Controversy30
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz5
Current news / social attention level

Publisher tools